Venus Concept Announces Australian Regulatory Approval for Venus Versa Pro
03 April 2024 - 1:30PM
Venus Concept Inc. (“Venus Concept” or the
“Company”) (NASDAQ: VERO), a global medical aesthetic
technology leader, today announced that it has Therapeutic Goods
Administration (TGA) clearance in Australia to market the Venus
Versa Pro system. The Venus Versa Pro combines the applicator of
the Venus Viva MD with the Venus Versa system which are both
approved in Australia and registered in Australian Register of
Therapeutic Goods (ARTG).
The Venus Versa Pro offers a total skin
rejuvenation experience by offering three powerful
technologies: Intense Pulsed Light (IPL) with SmartPulse™,
NanoFractional Radio Frequency with SmartScan™, and Venus'
proprietary (MP)2 technology. These technologies synergize to
enable customers to benefit from a wide variety of treatments to
enhance skin tone, improve tightness and smooth texture.
“We look forward to bringing our Venus Versa Pro system to
Australia, a major market to which we continue to commit investment
with a growing direct office presence,” said Dr. Hemanth Varghese,
President and Chief Operating Officer of Venus Concept. “Venus
Versa Pro continues to receive positive feedback from customers
regarding its multi-modal system capabilities and we look to bring
the device to more customers globally once approved with the
relevant local authorities.”
Cautionary Statement Regarding Forward-Looking
Statements
This communication contains “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933, as
amended and Section 21E of the Securities Exchange Act of 1934, as
amended. Any statements contained herein that are not of historical
facts may be deemed to be forward-looking statements. In some
cases, you can identify these statements by words such as such as
“anticipates,” “believes,” “plans,” “expects,” “projects,”
“future,” “intends,” “may,” “should,” “could,” “estimates,”
“predicts,” “potential,” and other similar expressions that are
predictions of or indicate future events and future trends. These
forward-looking statements are based on current expectations,
estimates, and projections about our business, and the industry in
which the Company operates and management's beliefs and assumptions
and are not guarantees of future performance or developments and
involve known and unknown risks, uncertainties, and other factors
that are in some cases beyond our control. As a result, any or all
of our forward-looking statements in this communication may turn
out to be inaccurate. Factors that could materially affect our
business operations and financial performance and condition
include, but are not limited to, those risks and uncertainties
described under Part II Item 1A-“Risk Factors” in our Quarterly
Reports on Form 10-Q and Part I Item 1A-“Risk Factors” in our
Annual Report on Form 10-K for the fiscal year ended December 31,
2023. You are urged to consider these factors carefully in
evaluating the forward-looking statements and are cautioned not to
place undue reliance on the forward-looking statements. The
forward-looking statements are based on information available to us
as of the date of this communication. Unless required by law, the
Company does not intend to publicly update or revise any
forward-looking statements to reflect new information or future
events or otherwise.
About Venus Concept
Venus Concept is an innovative global medical aesthetic
technology leader with a broad product portfolio of minimally
invasive and non-invasive medical aesthetic and hair restoration
technologies and reach in over 60 countries and 12 direct markets.
Venus Concept's product portfolio consists of aesthetic device
platforms, including Venus Versa, Venus Legacy, Venus Velocity,
Venus Fiore, Venus Viva, Venus Glow, Venus Bliss, Venus BlissMAX,
Venus Epileve, Venus Viva MD and AI.ME. Venus Concept's hair
restoration systems include NeoGraft® and the ARTAS iX® Robotic
Hair Restoration system. Venus Concept has been backed by leading
healthcare industry growth equity investors including EW Healthcare
Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude
Capital Management, Aperture Venture Partners, and Masters Special
Situations.
Investor Relations Contact:
ICR Westwicke on behalf of Venus Concept:
Mike Piccinino, CFA
VenusConceptIR@westwicke.com
Venus Concept (NASDAQ:VERO)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Venus Concept (NASDAQ:VERO)
Historical Stock Chart
Von Mai 2023 bis Mai 2024